Hikma Pharmaceuticals (DIFX:HIK) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DIFX:HIK Hikma Pharmaceuticals PLC DIFX:HIK
79 GF Score
Price $10.23
GF Value $14.00
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2026-07-21), Hikma Pharmaceuticals's Predictability Rank is 3.5-Stars. Hikma Pharmaceuticals's intrinsic value calculated from the Discounted Dividend model is $60.20 and current share price is $10.23. Consequently,

Hikma Pharmaceuticals's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is N/A.

DIFX:HIK vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Margin of Safety % (DCF Dividends Based) falls into.


DIFX:HIK
79GF Score
Hikma Pharmaceuticals PLC DIFX:HIK
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Margin of Safety % (DCF Dividends Based) Calculation

Hikma Pharmaceuticals's Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)=(Intrinsic Value: DCF (Dividends Based)-Current Price)/Intrinsic Value: DCF (Dividends Based)
=(0.00-10.23)/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Is Hikma Pharmaceuticals (DIFX:HIK) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $10.23 is trading 26.9% below its estimated GF Value™ of $14.00.

Key valuation signals for DIFX:HIK:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $14.00 vs. price of $10.23 (26.9% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the DIFX:HIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
79GF Score

Get the complete analysis for DIFX:HIK

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.23
Price
$14.00
GF Value